Valeant, Shkreli Put Profits Above Patients, Congress Says

Updated on
  • `$1 bn here we come,'' Martin Shkreli writes in e-mail
  • House oversight committee democrats release internal documents

Meet Martin Shkreli, Internet Star

Valeant Pharmaceuticals International Inc. and Turing Pharmaceuticals AG, both under congressional investigation over skyrocketing drug prices, were focused on making money before helping patients, members of Congress said internal documents obtained from the companies show.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.